Jefferson Antonio Buendia
MD, MSc, PhD
Researcher in Health Economics
Jefferson Antonio Buendía is a paediatric pulmonologist and joined the Health Economics Research Centre (HERC) in May 2023. He is currently working on economic evaluations in controlled clinical trials and estimation of the economic burden of disease.
Jefferson is an associate professor at the Faculty of Medicine of the University of Antioquia, Colombia where he has worked for more than 15 years in economic evaluations of medicines and health technologies in children's health and respiratory medicine.
He obtained his PhD in pharmacology at the University of Buenos Aires, where he worked on evaluating the impact of genetic markers on the pharmacokinetics of immunosuppressants in children with liver transplants. Jefferson obtained his MSc in clinical epidemiology at the Universidad de la Frontera in Chile, evaluating the cost-effectiveness of monoclonal antibodies in breast cancer in Colombia.
He has authored more than 100 publications in high-impact journals such as The Lancet, JAMA and Pharmacoeconomics. He is currently a collaborator in the Global Burden of Disease Study with the Institute for Health Metrics at the University of Washington.
Jefferson’s research interests lie in evaluation of the economic impact and cost-effectiveness of new drugs and effectiveness of biomarkers in personalised medicine.
Recent publications
-
Corticosteroids for the treatment of respiratory infection by Mycoplasma pneumoniae in children: A cost‐utility analysis
Journal article
Buendía JA. and Patiño DG., (2023), Pediatric Pulmonology
-
Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
Journal article
Shin YH. et al, (2023), Allergy
-
Risk factors associated with pulmonary exacerbations in pediatric patients with cystic fibrosis
Journal article
Teper A. et al, (2023), Archivos Argentinos de Pediatria
-
Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension.
Journal article
Buendia JA. et al, (2023), Expert Rev Pharmacoecon Outcomes Res, 1 - 7
-
Effectiveness of high-dose vitamin D supplementation to reduce the incidence rate of repeat episodes of pneumonia in children: A systematic review.
Journal article
Buendía JA. et al, (2023), Pediatr Pulmonol